Brje J Ljungberg

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4369118/borje-j-ljungberg-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235	13,556	51	112
papers	citations	h-index	g-index
255	16,127 ext. citations	5.9	6.04
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
235	Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years <i>PLoS ONE</i> , 2022 , 17, e0261124	3.7	O
234	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update <i>European Urology</i> , 2022 ,	10.2	29
233	Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study <i>European Urology Open Science</i> , 2022 , 39, 22-28	0.9	1
232	Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. <i>European Urology Open Science</i> , 2022 , 40, 38-45	0.9	O
231	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma <i>European Urology</i> , 2021 ,	10.2	4
230	Risk Prediction for Renal Cell Carcinoma: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) Prospective Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 507-512	4	O
229	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-nalle Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 79, 339-342	10.2	42
228	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 3823-3831	4	1
227	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021 , 128, 386-394	5.6	4
226	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e92-e99	3.3	5
225	Soft Drink and Juice Consumption and Renal Cell Carcinoma Incidence and Mortality in the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1270-1274	4	3
224	A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure. <i>Quality of Life Research</i> , 2021 , 30, 2663-2670	3.7	0
223	Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor. <i>BMC Cancer</i> , 2021 , 21, 604	4.8	3
222	Patient-reported outcome measures of abdominal wall morbidity after flank incision for open partial nephrectomy. <i>BJU International</i> , 2021 , 128, 497-503	5.6	1
221	Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. <i>PLoS ONE</i> , 2021 , 16, e0253236	3.7	5
220	Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. <i>European Journal of Cancer Prevention</i> , 2021 ,	2	4
219	Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. <i>Journal of Clinical Pathology</i> , 2021 , 74, 216-222	3.9	3

218	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021 , 4, 473-482	6.7	7
217	Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021 , 4, 22-41	6.7	14
216	A tactile resonance sensor for prostate cancer detection - evaluation on human prostate tissue. Biomedical Physics and Engineering Express, 2021,	1.5	1
215	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. World Journal of Urology, 2021, 39, 3377-3383	4	1
214	Validation of data quality in the National Swedish Kidney Cancer Register. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 142-148	1.6	3
213	Increased risk for renal cell carcinoma in end stage renal disease - a population-based case-control study. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 209-214	1.6	O
212	The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium. <i>PLoS Medicine</i> , 2021 , 18, e1003786	11.6	1
211	Inflammatory response markers and survival prediction in patients with renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2021 , 1-6	1.6	O
21 0	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020 , 78, 21-28	10.2	141
209	The renal cell cancer database Sweden (RCCBaSe) - a new register-based resource for renal cell carcinoma research. <i>Scandinavian Journal of Urology</i> , 2020 , 54, 235-240	1.6	5
208	Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1654-16	5 6 4	1
207	Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 521-525	2.8	3
206	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020 , 3, 433-452	6.7	9
205	Targeted therapy for metastatic renal cell carcinoma. <i>The Cochrane Library</i> , 2020 , 10, CD012796	5.2	13
204	Combining epigenetic and clinicopathological variables improves specificity in prognostic prediction in clear cell renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2020 , 18, 435	8.5	1
203	Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology, 2020, 54, 487-492	1.6	O
202	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , 2020 , 3, 57-72	6.7	23
201	One-carbon metabolism biomarkers and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , 2019 , 145, 2349-235	. 3·5	3

200	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019 , 76, 368-380	10.2	26
199	Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). <i>Scandinavian Journal of Urology</i> , 2019 , 53, 14-20	1.6	9
198	Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis. <i>Cancer Management and Research</i> , 2019 , 11, 1289-1297	3.6	2
197	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. <i>European Urology</i> , 2019 , 75, 799-810	10.2	597
196	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019 , 9, 11	5.3	9
195	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e345-e355	3.3	13
194	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2019 , 76, 151-156	10.2	125
193	Interactions between TGF-Itype I receptor and hypoxia-inducible factor-Imediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma. <i>Cell Cycle</i> , 2019 , 18, 2141-2156	4.7	13
192	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019 , 27, 1589-1598	5.3	15
191	An in-vitro assay using human spermatozoa to detect toxicity of biologically active substances. <i>Scientific Reports</i> , 2019 , 9, 14525	4.9	2
190	Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. <i>European Urology Focus</i> , 2019 , 5, 949-957	5.1	6
189	Association between occurrence of urinary bladder cancer and treatment with statin medication. <i>Turkish Journal of Urology</i> , 2019 , 45, 97-102	1.3	1
188	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019 , 2, 141-149	6.7	42
187	The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. <i>PLoS Medicine</i> , 2019 , 16, e1002724	11.6	38
186	DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2019 , 19, 65	4.8	16
185	Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival: Results from a European Multicentre Database (RECUR). <i>European Urology</i> , 2019 , 75, 261-264	10.2	16
184	Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. <i>European Urology Focus</i> , 2019 , 5, 857-866	5.1	46
183	Occurrence of abdominal bulging and hernia after open partial nephrectomy: a retrospective cohort study. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 54-58	1.6	5

Prostate cancer detection ex vivo combining Raman spectroscopy and tactile resonance technology. <i>IFMBE Proceedings</i> , 2018 , 193-196	0.2	
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018 , 73, 311-315	10.2	104
Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018 , 1, 512-523	6.7	12
Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study). <i>Research and Reports in Urology</i> , 2018 , 10, 181-187	1.3	1
VHL status regulates transforming growth factor-Bignaling pathways in renal cell carcinoma. <i>Oncotarget</i> , 2018 , 9, 16297-16310	3.3	8
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change	10.2	3
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018 , 74, 805-809	10.2	47
Pre-diagnostic circulating insulin-like growth factor-I and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2018 , 143, 2351-235	5 <mark>8</mark> 5	11
Evaluation of the diagnostic accuracy of UBC Rapid in bladder cancer: a Swedish multicentre study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 293-300	1.6	13
Second-look resection for primary stage T1 bladder cancer: a population-based study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 301-307	1.6	10
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e15-541.e22	2.8	17
Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 15724	17.4	50
Spinal analgesia improves surgical outcome after open nephrectomy for renal cell carcinoma: a randomized controlled study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 277-281	1.6	4
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 71, 426	-436	89
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 71, 719-722	10.2	52
Reduced number of CD169 macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. <i>Prostate</i> , 2017 , 77, 1468-1477	4.2	25
Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 747-754	10.2	27
Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the NORENCA-I study). <i>Scandinavian Journal of Urology</i> , 2017 , 51, 360-366	1.6	9
	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. European Urology, 2018, 73, 311-315 Systematic Review of the Management of Local Kidney Cancer Relapse. European Urology Oncology, 2018, 1, 512-523 Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study). Research and Reports in Urology, 2018, 10, 181-187 VHL status regulates transforming growth factor-Bignaling pathways in renal cell carcinoma. Oncotarget, 2018, 9, 16297-16310 A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 2018, 74, 805-809 Pre-diagnostic circulating insulin-like growth factor-l and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2018, 143, 2351-235 Evaluation of the diagnostic accuracy of UBC Rapid in bladder cancer: a Swedish multicentre study. Scandinavian Journal of Urology, 2017, 51, 293-300 Second-look resection for primary stage T1 bladder cancer: a population-based study. Scandinavian Journal of Urology, 2017, 51, 301-307 Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology. Seminars and Original Investigations, 2017, 35, 541-e15-541.e22 Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nature Communications, 2017, 8, 15724 Spinal analgesia improves surgical outcome after op	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. European Urology, 2018, 73, 311-315 Systematic Review of the Management of Local Kidney Cancer Relapse. European Urology Oncology, 2018, 15, 12-523 Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study). Research and Reports in Urology, 2018, 10, 181-187 VHL status regulates transforming growth factor-Bignaling pathways in renal cell carcinoma. Oncotarget, 2018, 9, 16297-16310 A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition. The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 2018, 74, 805-809 Pre-diagnostic circulating insulin-like growth factor-l and bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2018, 143, 2351-23585 Evaluation of the diagnostic accuracy of UBC Rapid in bladder cancer: a Swedish multicentre study. Scandinavian Journal of Urology, 2017, 51, 293-300 Second-look resection for primary stage T1 bladder cancer: a population-based study. Scandinavian Journal of Urology, 2017, 51, 301-307 Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Concology Seminars and Original Investigations, 2017, 35, 541-e15-541-e22 Genome-wide association study identifies multiple risk loci for renal cell carcinoma: a randomized controlled study. Scandinavian Journal of Urology, 2017, 51, 71, 745-744 S

164	Targeted therapy for metastatic renal cell carcinoma. The Cochrane Library, 2017,	5.2	4
163	Prostate Cancer Detection with a Tactile Resonance Sensor-Measurement Considerations and Clinical Setup. <i>Sensors</i> , 2017 , 17,	3.8	12
162	Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 14-20	1.6	17
161	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016 , 69, 660-673	10.2	276
160	The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. <i>European Urology</i> , 2016 , 70, 901-905	10.2	32
159	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. <i>European Urology</i> , 2016 , 70, 705-706	10.2	29
158	Impact of quality indicators on adherence to National and European guidelines for renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 2-8	1.6	17
157	DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC). <i>Tumor Biology</i> , 2016 , 37, 10219-28	2.9	12
156	Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. <i>World Journal of Urology</i> , 2016 , 34, 1081-6	4	126
155	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016 , 25, 1203-14	5.6	20
154	Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. <i>European Urology</i> , 2016 , 70, 265-80	10.2	57
153	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. <i>European Radiology</i> , 2016 , 26, 2798-807	8	25
152	Transforming growth factor-promotes aggressiveness and invasion of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 35917-35931	3.3	26
151	Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73. <i>European Urology</i> , 2016 , 69, e119-20	10.2	3
150	Reply to Jae Heon Kim's Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73. <i>European Urology</i> , 2016 , 70, e141-e142	10.2	
149	Author Reply. <i>Urology</i> , 2016 , 93, 122-3	1.6	
148	Nephron Sparing Surgery Associated With Better Survival Than Radical Nephrectomy in Patients Treated for Unforeseen Benign Renal Tumors. <i>Urology</i> , 2016 , 93, 117-23	1.6	13
147	Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 292	2- 1 .6	23

(2014-2015)

146	Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 290-5	1.6	24
145	Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , 2015 , 136, E423-31	7.5	15
144	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. <i>Radiology</i> , 2015 , 277, 114-23	20.5	49
143	TERT promoter mutations in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2015 , 136, 2448-52	7.5	36
142	Use of bacillus Calmette-Gufin in stage T1 bladder cancer: Long-term observation of a population-based cohort. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 127-32	1.6	10
141	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv279	9.7	107
140	Alcohol consumption and the risk of renal cancers in the European prospective investigation into cancer and nutrition (EPIC). <i>International Journal of Cancer</i> , 2015 , 137, 1953-66	7.5	19
139	Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015 , 23, 334-42	1.9	10
138	Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden. <i>BioMed Research International</i> , 2015 , 2015, 456040	3	14
137	EAU guidelines on renal cell carcinoma: 2014 update. European Urology, 2015, 67, 913-24	10.2	1627
137	EAU guidelines on renal cell carcinoma: 2014 update. <i>European Urology</i> , 2015 , 67, 913-24 The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991	10.2 3·7	1627 14
	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with		
136	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991 Overall survival (OS) in Swedish RCC patients treated 2000\(\textit{Z}\)012: Update of the RENCOMP study	3.7	
136 135	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991 Overall survival (OS) in Swedish RCC patients treated 2000\(\textit{Z012}\): Update of the RENCOMP study <i>Journal of Clinical Oncology</i> , 2015 , 33, 413-413	3.7	14
136 135 134	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991 Overall survival (OS) in Swedish RCC patients treated 2000\(\tilde{D}\)012: Update of the RENCOMP study <i>Journal of Clinical Oncology</i> , 2015 , 33, 413-413 Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014 , 35, 1737-44 Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human</i>	3·7 2.2 4.6	33
136 135 134	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991 Overall survival (OS) in Swedish RCC patients treated 2000\(\textit{\textit{2012}}\): Update of the RENCOMP study <i>Journal of Clinical Oncology</i> , 2015 , 33, 413-413 Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014 , 35, 1737-44 Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98 Anthropometric measures and bladder cancer risk: a prospective study in the EPIC cohort.	3.7 2.2 4.6 5.6	14 33 101 22
136 135 134 133	The Axl-Regulating Tumor Suppressor miR-34a Is Increased in ccRCC but Does Not Correlate with Axl mRNA or Axl Protein Levels. <i>PLoS ONE</i> , 2015 , 10, e0135991 Overall survival (OS) in Swedish RCC patients treated 2000\(\textit{2000}\)2012: Update of the RENCOMP study <i>Journal of Clinical Oncology</i> , 2015 , 33, 413-413 Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014 , 35, 1737-44 Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014 , 23, 1387-98 Anthropometric measures and bladder cancer risk: a prospective study in the EPIC cohort. <i>International Journal of Cancer</i> , 2014 , 135, 2918-29 The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.	3·7 2.2 4.6 5.6 7·5	14 33 101 22

128	Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 231-8	1.6	58
127	Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. <i>American Journal of Epidemiology</i> , 2014 , 180, 810-20	3.8	24
126	Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 445-52	1.6	15
125	Circulating biomarkers of one-carbon metabolism in relation to renal cell carcinoma incidence and survival. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	19
124	Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 334-40	1.6	23
123	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
122	Functional results after orthotopic bladder substitution: a prospective multicentre study comparing four types of neobladder. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 90-8	1.6	6
121	Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , 2013 , 132, 635-44	7.5	23
120	Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. <i>European Urology</i> , 2013 , 64, 799-810	10.2	60
119	Re: comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis: s. P. Kim, R. H. Thompson, s. A. Boorjian, C. J. Weight, L. C. Han, m. H. Murad, N. D. Shippee, p. J. Erwin, B. A. Costello, g. K. Chow	2.5	3
118	Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. <i>Scandinavian Journal of Urology</i> , 2013 , 47, 483-90	1.6	12
117	The role of metastasectomy in renal cell carcinoma in the era of targeted therapy. <i>Current Urology Reports</i> , 2013 , 14, 19-25	2.9	53
116	Indentation loading response of a resonance sensordiscriminating prostate cancer and normal tissue. <i>Journal of Medical Engineering and Technology</i> , 2013 , 37, 416-23	1.8	10
115	Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma. <i>Acta Oncolgica</i> , 2013 , 52, 159-65	3.2	7
114	N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2055-65	4	22
113	CpG dinucleotide-specific hypermethylation of the TNS3 gene promoter in human renal cell carcinoma. <i>Epigenetics</i> , 2013 , 8, 739-47	5.7	15
112	Telomere length in relation to immunological parameters in patients with renal cell carcinoma. <i>PLoS ONE</i> , 2013 , 8, e55543	3.7	18
111	Single nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2013 , 8, e58396	3.7	4

(2011-2013)

110	Metabolic factors associated with risk of renal cell carcinoma. PLoS ONE, 2013, 8, e57475	3.7	59
109	Systematic review of oncological outcomes following surgical management of localised renal cancer. <i>European Urology</i> , 2012 , 61, 972-93	10.2	232
108	Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. <i>BJU International</i> , 2012 , 109, 1134-9	5.6	22
107	Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. <i>European Urology</i> , 2012 , 62, 1097-117	10.2	151
106	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. <i>Cancer Treatment Reviews</i> , 2012 , 38, 127-32	14.4	6
105	Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. <i>BMC Research Notes</i> , 2012 , 5, 216	2.3	16
104	Fruit and vegetable consumption and risk of aggressive and non-aggressive urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition. <i>European Journal of Cancer</i> , 2012 , 48, 3267-77	7.5	22
103	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. <i>Human Molecular Genetics</i> , 2012 , 21, 456-62	5.6	74
102	Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. <i>Scandinavian Journal of Urology and Nephrology</i> , 2012 , 46, 14-8		18
101	Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 902-10	7	37
100	Nephron-Sparing Surgery Strategy: The Current Standard for the Treatment of Localised Renal Cell Carcinoma. <i>European Urology Supplements</i> , 2011 , 10, e49-e51	0.9	1
99	The notch and TGF-Bignaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2011 , 6, e23057	3.7	47
98	Defecation disturbances after cystectomy for urinary bladder cancer. <i>BJU International</i> , 2011 , 108, 196	-2 9 18	12
97	Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. <i>Nature Genetics</i> , 2011 , 43, 60-5	36.3	199
96	Words of wisdom: Re: Can partial nephrectomy preserve renal function and modify survival in comparison with radical nephrectomy?. <i>European Urology</i> , 2011 , 60, 595-6	10.2	0
95	Metastatic potential in renal cell carcinomas 🛭 cm: Swedish Kidney Cancer Quality Register data. <i>European Urology</i> , 2011 , 60, 975-82	10.2	75
94	The epidemiology of renal cell carcinoma. <i>European Urology</i> , 2011 , 60, 615-21	10.2	644
93	Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>International Journal of Cancer</i> , 2011 , 128, 2695-708	7.5	45

92	Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2011 , 128, 2971-9	7.5	23
91	Red meat, dietary nitrosamines, and heme iron and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 555-9	4	37
90	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. <i>Nature Genetics</i> , 2010 , 42, 978-84	36.3	408
89	Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. <i>BJU International</i> , 2010 , 105, 1107-17	5.6	9
88	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. <i>Genes and Cancer</i> , 2010 , 1, 152-163	2.9	230
87	Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010 , 44, 69-75		11
86	Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. <i>World Journal of Urology</i> , 2010 , 28, 247-52	4	71
85	EAU guidelines on renal cell carcinoma: the 2010 update. <i>European Urology</i> , 2010 , 58, 398-406	10.2	1041
84	Preoperative carbohydrate drink improves postoperative quality of life after urological surgery: a randomized study. <i>International Journal of Urological Nursing</i> , 2009 , 3, 64-68	0.8	
83	Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. <i>PLoS ONE</i> , 2009 , 4, e4350	3.7	44
82	Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas. <i>PLoS ONE</i> , 2009 , 4, e6039	3.7	13
81	Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2009 , 4, e7575	3.7	36
80	Expression of erythropoietin and its receptor in human renal cell carcinoma. <i>Tumor Biology</i> , 2009 , 30, 86-92	2.9	15
79	Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma. <i>Acta Oncolgica</i> , 2009 , 48, 909-14	3.2	11
78	Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. <i>Clinical Cancer Research</i> , 2009 , 15, 4742-9	12.9	106
77	High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. <i>BMC Cancer</i> , 2009 , 9, 152	4.8	165
76	Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. <i>European Urology</i> , 2009 , 55, 851-63	10.2	113
75	The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. International Journal of Cancer, 2009 , 125, 783-90	7.5	43

(2007-2009)

74	A prospective analysis of the association between macronutrient intake and renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2009 , 125, 982-7	7.5	23
73	Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. <i>International Journal of Cancer</i> , 2009 , 125, 2643-51	7.5	36
72	CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. <i>BMC Clinical Pathology</i> , 2009 , 9, 9	3	24
71	Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. <i>Cancer Research</i> , 2009 , 69, 2896-901	10.1	67
70	A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009 , 43, 271-6		22
69	Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009 , 43, 293-9		15
68	Gull del carcinoma de clulas renales. Actas Urolgicas Espalolas, 2009 , 33, 270-279	0.7	1
67	Contemporary status of open nephron-sparing surgery in renal cell carcinoma. <i>Archivio Italiano Di Urologia Andrologia</i> , 2009 , 81, 61-4	1.6	2
66	Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. <i>American Journal of Epidemiology</i> , 2008 , 167, 438-46	3.8	134
65	Explanatory models for a tactile resonance sensor system-elastic and density-related variations of prostate tissue in vitro. <i>Physiological Measurement</i> , 2008 , 29, 729-45	2.9	17
64	Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. Journal of Clinical Investigation, 2008 , 118, 217-28	15.9	142
63	Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. <i>BJU International</i> , 2008 , 101, 480-4	5.6	33
62	Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. <i>BJU International</i> , 2007 , 100, 556-60	5.6	85
61	Reply to Andrea Minervini, Sergio Serni, Marco Carini and Claudio Di Cristofano Letter to the Editor re: Anders Lidgren, Ylva Hedberg, Kjell Grankvist, Torgny Rasmuson, Anders Bergh and Bije Ljungberg. Hypoxia-Inducible Factor 1Æxpression in Renal Cell Carcinoma Analyzed by Tissue	10.2	
60	Renal cell carcinoma guideline. <i>European Urology</i> , 2007 , 51, 1502-10	10.2	382
59	Spatial variations in prostate tissue histology as measured by a tactile resonance sensor. <i>Physiological Measurement</i> , 2007 , 28, 1267-81	2.9	8
58	Prognostic markers in renal cell carcinoma. <i>Current Opinion in Urology</i> , 2007 , 17, 303-8	2.8	69
57	Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 2007 , 41, 5-9		9

56	Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. <i>Tumor Biology</i> , 2007 , 28, 158-64	2.9	24
55	Prostate tissue stiffness as measured with a resonance sensor system: a study on silicone and human prostate tissue in vitro. <i>Medical and Biological Engineering and Computing</i> , 2006 , 44, 593-603	3.1	42
54	Prostate cancer detection with an improved resonance sensor system: parameter evaluation in a silicone model and on human prostate tissue in vitro. <i>Medical and Biological Engineering and Computing</i> , 2006 , 44, 1053-9	3.1	10
53	Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. <i>European Urology</i> , 2006 , 50, 1272-7	10.2	59
52	Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). <i>International Journal of Cancer</i> , 2006 , 118, 728-38	7.5	141
51	Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). <i>International Journal of Cancer</i> , 2006 , 118, 3133-9	7.5	61
50	Resonance sensor measurements of stiffness variations in prostate tissue in vitroa weighted tissue proportion model. <i>Physiological Measurement</i> , 2006 , 27, 1373-86	2.9	35
49	Expression of human chorionic gonadotropin beta-subunit type I genes predicts adverse outcome in renal cell carcinoma. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 598-603	5.1	14
48	Endoglin (CD105) expression in human renal cell carcinoma. <i>BJU International</i> , 2006 , 97, 706-10	5.6	44
47	Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. <i>BJU International</i> , 2006 , 97, 1102-8	5.6	29
46	Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma. <i>BJU International</i> , 2006 , 98, 661-7	5.6	47
45	Gene expression profiling predicts survival in conventional renal cell carcinoma. <i>PLoS Medicine</i> , 2006 , 3, e13	11.6	154
44	Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma. <i>Tumor Biology</i> , 2005 , 26, 201-6	2.9	19
43	Adrenal metastasis in renal cell carcinoma: a recommendation for adjustment of the TNM staging system. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 39, 277-82		13
42	The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 1129-35	12.9	102
41	Serum insulin-like growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. <i>Acta Oncolgica</i> , 2004 , 43, 744-8	3.2	55
40	Prognostic factors in renal cell carcinoma. <i>Der Urologe</i> , 2004 , 43 Suppl 3, S119-20		12
39	Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins. <i>International Journal of Cancer</i> , 2004 , 109, 189-93	7.5	20

(1996-2004)

38	ErbB4 is downregulated in renal cell carcinomaa quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. <i>Acta Oncolgica</i> , 2004 , 43, 453-9	3.2	18
37	Status of pretreatment evaluation, treatment and follow-up regimens for renal cell carcinoma in the Nordic countries. <i>Scandinavian Journal of Urology and Nephrology</i> , 2003 , 37, 401-7		4
36	Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. <i>Urological Research</i> , 2003 , 31, 335-40		36
35	Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. <i>International Journal of Cancer</i> , 2002 , 102, 601-7	7.5	4º
34	Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. <i>Genes Chromosomes and Cancer</i> , 2002 , 35, 256-60	5	47
33	Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. <i>Acta Oncolgica</i> , 2002 , 41, 175-81	3.2	35
32	TUMOR ASSOCIATED TRYPSIN INHIBITOR AS A PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001 , 165, 959-962	2.5	30
31	Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000 , 34, 246-5	1	50
30	VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000 , 163, 343-347	2.5	180
29	Clinical significance of nm23 expression in renal cell carcinoma. <i>Urological Research</i> , 1999 , 27, 103-7		4
28	Cyclin-D1 expression in human renal-cell carcinoma. <i>International Journal of Cancer</i> , 1999 , 84, 268-72	7.5	36
27	Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. <i>International Journal of Cancer</i> , 1999 , 83, 486-90	7.5	33
			\
26	Lack of genetic changes at specific genomic sites separates renal oncocytomas from renal cell carcinomas. <i>Journal of Pathology</i> , 1998 , 184, 58-62	9.4	30
26 25		9.4	30
	Carcinomas. Journal of Pathology, 1998, 184, 58-62 Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate. Scandinavian Journal of Urology and Nephrology,	9.4	
25	Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997 , 31, 255-8 Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the		3
25	Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate. <i>Scandinavian Journal of Urology and Nephrology</i> , 1997, 31, 255-8 Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. <i>International Journal of Cancer</i> , 1997, 74, 233-6 Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the		3 23

20	Accuracy of clinical staging in non-seminomatous testicular cancera single centre experience of retroperitoneal lymph node dissection. <i>Scandinavian Journal of Urology and Nephrology</i> , 1995 , 29, 501-	6	5
19	Vein invasion in renal cell carcinoma: impact on metastatic behavior and survival. <i>Journal of Urology</i> , 1995 , 154, 1681-4	2.5	83
18	Serum acute phase reactants and prognosis in renal cell carcinoma. <i>Cancer</i> , 1995 , 76, 1435-9	6.4	50
17	Proliferation of human renal cell carcinoma studied with in vivo iododeoxyuridine labelling and immunohistochemistry. <i>Scandinavian Journal of Urology and Nephrology</i> , 1994 , 28, 135-40		6
16	Serum gamma-enolase and prognosis of patients with renal cell carcinoma. <i>Cancer</i> , 1993 , 72, 1324-8	6.4	14
15	Tumor-cell proliferation and prognosis in renal-cell carcinoma. <i>International Journal of Cancer</i> , 1993 , 55, 566-70	7.5	25
14	DNA fingerprinting of renal cell carcinoma with special reference to tumor heterogeneity. <i>Genes Chromosomes and Cancer</i> , 1993 , 6, 86-91	5	4
13	Multiple renal masses in patients with renal cell carcinoma: diagnostic pitfalls and surgical implications. <i>Scandinavian Journal of Urology and Nephrology</i> , 1992 , 26, 367-71		1
12	Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. <i>European Urology</i> , 1992 , 21, 160-3	10.2	33
11	Flow cytometric deoxyribonucleic acid analysis in stage I renal cell carcinoma. <i>Journal of Urology</i> , 1991 , 146, 697-9	2.5	45
10	Renal cell carcinoma in tissue culture secretes nondialyzable product that stimulates bone resorption in organ-cultured mouse calvaria. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 365-77	6.3	4
9	Genetic variation of haptoglobin and transferrin in relation to DNA content and stage in renal cell carcinoma. <i>Cancer</i> , 1989 , 63, 1138-42	6.4	3
8	Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 1989 , 23, 11-4		4
7	Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma. <i>Journal of Urology</i> , 1989 , 141, 1308-10	2.5	5
6	Deoxyribonucleic acid content in metastatic renal cell carcinoma: clinical implications. <i>Journal of Surgical Oncology</i> , 1988 , 4, 165-8		3
5	Renal cell carcinoma in a solitary kidney: late nephrectomy after 35 years and analysis of tumor deoxyribonucleic acid content. <i>Journal of Urology</i> , 1988 , 139, 350-2	2.5	9
4	A comparison of radiologic methods in the diagnosis of renal mass lesions. <i>Scandinavian Journal of Urology and Nephrology</i> , 1988 , 22, 187-96		10
3	Inverted papilloma with intussusception of the ureter. Case report. <i>Scandinavian Journal of Urology and Nephrology</i> , 1987 , 21, 147-9		8

LIST OF PUBLICATIONS

Prognostic value of deoxyribonucleic acid content in metastatic renal cell carcinoma. *Journal of Urology*, **1986**, 136, 801-4

2.5 68

6.4

DNA content in renal cell carcinoma with reference to tumor heterogeneity. *Cancer*, **1985**, 56, 503-8

167